Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Status Terminated

Clinical Trial Summary

The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives include determining if RAD001 treatment will improve hearing ability in NF2 patients. RAD001 is an oral drug that is approved by Food and Drug Administration (FDA) for other types of tumors, it is not approved by the FDA for treatment of NF2 related tumors.

Clinical Trial Description

This protocol is a Phase II, open-label, efficacy and safety study of single-agent RAD001 in patients with NF2. During the study, subjects will receive continuous daily oral treatment with RAD001 for up to 1 year or until tumor progression. Primary Objective: To determine whether RAD001 has an effect on the VS growth in patients with NF2 at a rate sufficient to submit the drug for further testing. Secondary Objectives: To determine whether RAD001 has an effect on the volume of other intracranial tumors, and to assess the effect of RAD001 on hearing function in patients with NF2 (when applicable). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01345136
Study type	Interventional
Source	Jonsson Comprehensive Cancer Center
Contact
Status	Terminated
Phase	Phase 2
Start date	July 1, 2015
Completion date	February 6, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05521048` - Doxycycline in Cutaneous Schwannoma (NF2)	Phase 1/Phase 2
Completed	`NCT01207687` - Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)	Phase 2
Completed	`NCT01767792` - Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas	Phase 2
Active, not recruiting	`NCT01552434` - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	Phase 1
Completed	`NCT01880749` - Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas	Early Phase 1
Recruiting	`NCT05130866` - Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas	Phase 2/Phase 3
Recruiting	`NCT04374305` - Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)	Phase 2
Completed	`NCT01125046` - Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas	Phase 2
Completed	`NCT03210285` - WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
Completed	`NCT02934256` - Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors	Phase 2
Completed	`NCT02104323` - Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors	Phase 2
Completed	`NCT02246231` - Effect of Implant Position on Magnetic Resonance Image Distortion	N/A
Terminated	`NCT02282917` - Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma	Early Phase 1
Completed	`NCT02129647` - Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas	Phase 2
No longer available	`NCT02589912` - Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients